Regenerx Biopharmaceuticals Stock Price, News & Analysis

RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) is a publicly traded, clinical-stage biopharmaceutical company specializing in the field of tissue protection, repair, and regeneration. The company's mission is to develop novel pharmaceuticals aimed at safeguarding and restoring tissue and organ function impaired by disease, trauma, or other pathological conditions.

RegeneRx's core focus is on advancing three distinct drug candidates through clinical development, each based on the company's proprietary thymosin beta 4 (Tβ4) technology. These candidates are:

• RGN-137: A topical gel intended for dermal wound healing.
• RGN-259: An ophthalmic solution aimed at treating dry eye syndrome and other corneal disorders.
• RGN-352: An injectable formulation designed for systemic therapeutic applications.

Currently, RegeneRx holds more than 75 issued patents or pending patent applications worldwide, which serve to protect multiple indications and applications for its product candidates.

RegeneRx has established significant partnerships in three major territories: the United States and Canada, China, and Pan Asia. These collaborations have been instrumental in advancing the clinical trials for RGN-259, particularly in the field of ophthalmology. Importantly, the financial burden of these developments is being borne by RegeneRx's partners, facilitating progress without imposing additional financial strain on the company.

Recent developments include a 1-for-100 reverse stock split that was effected on August 15, 2023. This strategic move aims to streamline the company's stock structure and improve its market position. Additionally, RegeneRx has filed Form 15 to suspend and terminate its reporting obligations with the SEC, a step that may influence its public trading status.

For further information, stockholders and interested parties are encouraged to visit www.regenerx.com or contact Mr. J.J. Finkelstein at 301.208.9191 or via email at jjfnk@regenerx.com.